Skip to main content



Inflammatory Arthritis and Hidradenitis Suppurativa

Dec 09, 2022

Hidradenitis suppurativa (HS) (also called acne inversa), is a chronic inflammatory skin disorder affecting apocrine gland-bearing skin in the axillae, groin, and under the breasts and is characterised by persistent or 

Read Article
A Multidimensional Approach in the Management of Axial Spondylarthritis Abstract 1510 by Jones et al studied the effect of lifestyle on treatment response in patients with axial spondylarthritis.
Lifestyle Modifications may enhance TNF Inhibitors in axSpA

Comparing Biosimilar Growth in the US, Germany, and Switzerland

Dec 05, 2022

The biosimilar landscape will change dramatically in 2023, following the successful rollouts in other countries in Europe. This analysis of the uptake and price of biologic therapy in Germany, Switzerland and the United States suggest that anticompetitive practices in the US could allow

Read Article
ACR meeting education

ACR22 Takeaways: Pre-RA, Lupus, PsA and AS

Nov 29, 2022

ACR22 Convergence left us bountiful with information from all over the world. Here are a few of my personal highlights and key takeaways. 

Read Article
Spondyloarthritis Topic Panel - #ACR22 SpA Panelists: Drs. Lianne Gensler, Antoni Chan, Akhil Sood, Eric Dein, Sheila Reyes, Catherine Sims @synovialjoints @AkhilSoodMD @ericdeinmd @RHEUMarampa @DrCassySims
Treatment Considerations in Axial Spondyloarthritis Dr. Lianne Gensler discusses treatment considerations in Axial SpA from #ACR22. -Abstract 0402 -Abstract 0388 -Abstract 0544 -Abstract 0545
TNFi cycling in axSpA: Results from CorEVITAS Registy study Dr. Rachel Tate ( @uptotate) reviews abstract #1499 presented at #ACR22.
scale decision balance question

The disconnect between objective inflammatory response and PROs in AxSpA

Nov 23, 2022

The assessment of disease activity in AxSpA involves the use of objective inflammatory response (OIR) and patient reported outcomes (PROs). In clinics, a combination of OIR and PROs are used to measure disease activity and response to treatment. OIR includes measurements such as CRP and MRI

Read Article
together solution

A Multidimensional Approach in the Management of Axial Spondylarthritis

Nov 21, 2022

There has been much focus on the pharmacologic management of axSpA. Despite optimal control of inflammation, symptoms of fatigue and pain can persist. Long term use of analgesics including opioids carries significant risks. Strategies to improve response to treatment in this population is

Read Article
RheumNow Podcast square

ACR 2022 Appraisal, Praise & Critique (11.18.2022)

Nov 18, 2022

It was great to be back at an ACR annual meeting, this one in Philadelphia - Philly was great. A walking town, rich in culture, history and good places to meet and mingle. 

I loved the city, but not the convention center (not easy to navigate). 

The meeting itself was very

Read Article

Gender Differences in Axial Spondyloarthritis

Nov 17, 2022

Rheumatic conditions such as SLE and RA exhibit female predominance. In contrast, increasing evidence suggests that gender differences occur in axial spondyloarthritis in terms of time to diagnosis, clinical manifestations, treatment outcomes and quality of life. The exact mechanisms are

Read Article
Best of

ACR Best Abstracts - Day 3

Nov 14, 2022

The last day was jammed with important reports and research including the late breaking abstracts. 


Read Article

The complexity of opioid use in spondyloarthritis

Nov 14, 2022

A few things we know about opioids: use is common; it’s not efficacious in the treatment of spondyloarthritis; and, there is an opioid epidemic and its users are stigmatized. Abstract 0402 is a retrospective study that looked at patients with psoriatic arthritis or ankylosing spondylitis in the

Read Article
Back Pain

Thinking Outside the Box: Novel Strategies for Early Detection of AxSpA

Nov 14, 2022

Strategies to identify patients with suspected inflammatory back pain in the general population is critical for timely and proper diagnosis.

Read Article
Curtis et al. Primary non-adherence to csDMARDs and b/tsDMARDs in RA/PsA/SpA. Medicare and commerically-insured patients. 20-44%! of new prescriptions not filled by 6 months. Higher for csDMARDs than b/tsDMARDs @RheumNow #ACR22 Abstr#2199
Are your SpA pts planning on conceiving? Be careful with NSAID use French study found age and NSAID use associated with longer time-to-conception. Factors not associated: smoking, BASDAI score, DMARD use #ACRBest Abs#1673 @RheumNow #ACR22
Ab1673 #ACR22: Time-to-Conception (T2C) in SpA Prosp, observ 88F, 56 pregnancy Subfertility in 45% F, T2C 16 mos Risks: age, NSAID Rx: NSAIDs (26%), steroids (9%), csDMARD (14%), biol (69%) No control grp - Is it cause or correlate? 2020 Repro G/L rec d/c NSAID @RheumNow #ACRBest
Hamroun et al. Preconceptual NSAID use assoc impaired fertility in SpA, HR 3.01 for time-to-conception @RheumNow #ACR22 Abstr#1673
Dr S Hamroun shares their study data on factors assoc w/ time-to-conception in ♀️ w/ SpA: ❗Pre-conceptional NSAID use ❗Age Thought-provoking. Time to re-evaluate our NSAID prescribing practices for ♀️ SpA? #ACR22 @RheumNow ABST#1673
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target. #ACR22 @Rheumnow @rheumarhyme @trishiemd

Dual inhibition of IL17A and IL17F in AxSpA

Nov 14, 2022

A new target for treatment in AxSpA is the dual inhibition of IL17A and IL17F (IL17A/F). IL17A is a key driver of the inflammation in the AxSpA and Psoriatic Arthritis (PsA). IL17A and its structurally related IL17F share biologic functional properties. Inhibition of both cytokines (IL17A/F)

Read Article
L14 #ACR22 Bimekizumab BE MOBILE 1 and 2 Sustained efficacy to Wk52. ASAS40 in BKZ incr from W16 (47% nrAxSpA, 45% AS) to W52 (61%, 58%). Efficacy in TNF-naive & TNF-failure. AEs: Nasopharyngitis (12% nrAxSpA, 9% AS), URI (9, 6%), candidiasis (7, 6%), COVID (7, 2%) @RheumNow
L15 #ACR22 SURPASS: SEC vs bsADA (SDZ-ADL) on radiographic progression of AS P3b: SEC 150 mg v SEC 300 v SDZ-ADL Wk 104: no radiographic progression in 66%, 67%, 66% - no statistical significance Hard to assess as overall, low rate of progression @RheumNow